Global Cancer Monoclonal Antibodies Market Sales Revenue Clinical Trials Pipeline Report

he recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has enabled the pharma companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system so as to develop more efficient mAbs.

Download Report:

https://www.kuickresearch.com/report-Global-Cancer-Monoclonal-Antibodies-Market-&-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Global Cancer Monoclonal Antibodies Market & Pipeline Insight" Table of Contents

1. Introduction to Monoclonal Antibodies
1.1 History of Development of Monoclonal Antibodies
1.2 Working of Monoclonal Antibodies

2. Types of Monoclonal Antibodies
2.1 Naked Monoclonal Antibodies
2.2 Conjugated Monoclonal Antibodies
2.2.1 Radiolabeled Antibodies
2.2.2 Chemolabeled Antibodies
2.2.3 Immunotoxins

3. Mechanisms of Monoclonal Antibodies
3.1 Tumor Antigens as Targets of Antibodies
3.2 Development of Antibodies for Clinical Purposes
3.3 Complement Dependent Cytotoxicity (CDC)
3.4 Signal Transduction Changes

4. Need for Monoclonal Antibodies for Cancer Treatment

5. Cancer Monoclonal Antibodies Market Overview
5.1 Current Market Scenario
5.2 Clinical Pipeline Insight

6. Cancer Monoclonal Antibodies Market Dynamics
6.1 Favorable Parameters
6.2 Challenges
6.3 Future Growth Outlook

7. Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country
7.1 Phase Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase I
7.6 Phase I/II
7.7 Phase II
7.8 Phase II/III
7.9 Phase III
7.10 Preregistration
7.11 Registered

8. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country

9. Suspended & Discontinued Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country
9.1 No Development Reported
9.2 Discontinued
9.3 Market Withdrawal
9.4 Suspended

10. Competitive Landscape
10.1 Abbvie
10.2 Amgen
10.3 Bayer HealthCare
10.4 Biogen Idec
10.5 Eli Lilly
10.6 Genmab
10.7 Gilead Sciences
10.8 GlaxoSmithKline
10.9 Novartis
10.10 Pfizer
10.11 Roche
10.12 Seattle Genetics

Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Figure 2-1: Types of Monoclonal Antibodies
Figure 5-1: Global Biologics Market Classification
Figure 5-2: Share of Monoclonal Antibodies in Biologics Market (%), 2013 & 2020
Figure 5-3: Global Market for Monoclonal Antibodies (US$ Billion), 2013-2020
Figure 5-4: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (%), 2014
Figure 5-5: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (Number), 2014
Figure 5-6: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
Figure 5-7: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014
Figure 5-8: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
Figure 5-9: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014
Figure 5-10: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
Figure 5-11: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.